96 related articles for article (PubMed ID: 18069261)
21. NF-κB dysregulation in multiple myeloma.
Matthews GM; de Matos Simoes R; Dhimolea E; Sheffer M; Gandolfi S; Dashevsky O; Sorrell JD; Mitsiades CS
Semin Cancer Biol; 2016 Aug; 39():68-76. PubMed ID: 27544796
[TBL] [Abstract][Full Text] [Related]
22. Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma.
Fuchs O
Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):16-34. PubMed ID: 23534949
[TBL] [Abstract][Full Text] [Related]
23. Novel players in multiple myeloma pathogenesis: role of protein kinases CK2 and GSK3.
Piazza F; Manni S; Semenzato G
Leuk Res; 2013 Feb; 37(2):221-7. PubMed ID: 23174190
[TBL] [Abstract][Full Text] [Related]
24. Novel c-Myc G4 stabilizer EP12 promotes myeloma cytotoxicity by disturbing NF-κB signaling.
Yao R; Zhang Y; Zeng Y; Zhang Y; Liu L; Gao J
Exp Cell Res; 2023 Oct; 431(1):113759. PubMed ID: 37625768
[TBL] [Abstract][Full Text] [Related]
25. NF-kappaB in the pathogenesis and treatment of multiple myeloma.
Li ZW; Chen H; Campbell RA; Bonavida B; Berenson JR
Curr Opin Hematol; 2008 Jul; 15(4):391-9. PubMed ID: 18536579
[TBL] [Abstract][Full Text] [Related]
26. Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma.
Chinen Y; Kuroda J; Shimura Y; Nagoshi H; Kiyota M; Yamamoto-Sugitani M; Mizutani S; Sakamoto N; Ri M; Kawata E; Kobayashi T; Matsumoto Y; Horiike S; Iida S; Taniwaki M
Cancer Res; 2014 Dec; 74(24):7418-29. PubMed ID: 25269480
[TBL] [Abstract][Full Text] [Related]
27. Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targets.
Lawasut P; Groen RW; Dhimolea E; Richardson PG; Anderson KC; Mitsiades CS
Semin Oncol; 2013 Oct; 40(5):537-48. PubMed ID: 24135398
[TBL] [Abstract][Full Text] [Related]
28. Initial genome sequencing and analysis of multiple myeloma.
Chapman MA; Lawrence MS; Keats JJ; Cibulskis K; Sougnez C; Schinzel AC; Harview CL; Brunet JP; Ahmann GJ; Adli M; Anderson KC; Ardlie KG; Auclair D; Baker A; Bergsagel PL; Bernstein BE; Drier Y; Fonseca R; Gabriel SB; Hofmeister CC; Jagannath S; Jakubowiak AJ; Krishnan A; Levy J; Liefeld T; Lonial S; Mahan S; Mfuko B; Monti S; Perkins LM; Onofrio R; Pugh TJ; Rajkumar SV; Ramos AH; Siegel DS; Sivachenko A; Stewart AK; Trudel S; Vij R; Voet D; Winckler W; Zimmerman T; Carpten J; Trent J; Hahn WC; Garraway LA; Meyerson M; Lander ES; Getz G; Golub TR
Nature; 2011 Mar; 471(7339):467-72. PubMed ID: 21430775
[TBL] [Abstract][Full Text] [Related]
29. RNA interference for multiple myeloma therapy: targeting signal transduction pathways.
Guo J; McKenna SL; O'Dwyer ME; Cahill MR; O'Driscoll CM
Expert Opin Ther Targets; 2016; 20(1):107-21. PubMed ID: 26190583
[TBL] [Abstract][Full Text] [Related]
30. Aberrant non-canonical NF-κB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma.
Ang DA; Carter JM; Deka K; Tan JHL; Zhou J; Chen Q; Chng WJ; Harmston N; Li Y
Nat Commun; 2024 Mar; 15(1):2513. PubMed ID: 38514625
[TBL] [Abstract][Full Text] [Related]
31. [Progresses in IkB kinase and related signal transduction].
Shen F; Cheng GF
Sheng Li Ke Xue Jin Zhan; 2001 Jan; 32(1):80-2. PubMed ID: 12545787
[No Abstract] [Full Text] [Related]
32. Synopsis of a roundtable on validating novel therapeutics for multiple myeloma.
Dalton W; Anderson KC
Clin Cancer Res; 2006 Nov; 12(22):6603-10. PubMed ID: 17121878
[TBL] [Abstract][Full Text] [Related]
33. Gene therapy for multiple myeloma.
Adachi Y; Yoshio-Hoshino N; Nishimoto N
Curr Gene Ther; 2008 Aug; 8(4):247-55. PubMed ID: 18691020
[TBL] [Abstract][Full Text] [Related]
34. A critical role for the NFkB pathway in multiple myeloma.
Demchenko YN; Kuehl WM
Oncotarget; 2010 May; 1(1):59-68. PubMed ID: 20890394
[TBL] [Abstract][Full Text] [Related]
35. Integration of Genomics Into Treatment: Are We There Yet?
Morgan GJ; Jones JR
Am Soc Clin Oncol Educ Book; 2017; 37():569-574. PubMed ID: 28561666
[TBL] [Abstract][Full Text] [Related]
36. Multiple myeloma.
Dalton WS; Bergsagel PL; Kuehl WM; Anderson KC; Harousseau JL
Hematology Am Soc Hematol Educ Program; 2001; ():157-77. PubMed ID: 11722983
[TBL] [Abstract][Full Text] [Related]
37. Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease.
Kyriazoglou A; Ntanasis-Stathopoulos I; Terpos E; Fotiou D; Kastritis E; Dimopoulos MA; Gavriatopoulou M
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):57-62. PubMed ID: 31734019
[TBL] [Abstract][Full Text] [Related]
38. [Myeloma stem/progenitor cells as new targets for therapy of multiple myeloma--review].
Ma YL; Hou J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1459-64. PubMed ID: 19099665
[TBL] [Abstract][Full Text] [Related]
39. Gene therapy approaches for multiple myeloma.
Russell SJ; Dunbar CE
Semin Hematol; 2001 Jul; 38(3):268-75. PubMed ID: 11486315
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression.
Croucher DC; Richards LM; Tsofack SP; Waller D; Li Z; Wei EN; Huang XF; Chesi M; Bergsagel PL; Sebag M; Pugh TJ; Trudel S
Nat Commun; 2021 Nov; 12(1):6322. PubMed ID: 34732728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
